Literature DB >> 24473197

Contribution of NKX2-3 polymorphisms to inflammatory bowel diseases: a meta-analysis of 35358 subjects.

XiaoCheng Lu1, Linjun Tang1, Kai Li2, JinYu Zheng2, Penglai Zhao2, Yi Tao2, Li-Xin Li2.   

Abstract

Polymorphisms in NKX2-3 gene have been inconsistently associated with Crohn's disease (CD) and ulcerative colitis (UC). To generate large-scale evidence on whether NKX2-3 polymorphisms are associated with CD or UC susceptibility we have conducted a meta-analysis of 17 studies involving 17329 patients and 18029 controls. A significantly increased CD or UC risk was observed in persons carrying a G allele at rs10883365 polymorphism (A/G) compared with those with a A allele. (OR = 1.226, 95%CI: 1.177-1.277 and OR = 1.274, 95%CI: 1.175-1.382 respectively). In the subgroup analysis, a significantly increased CD risk was found in both Europeans and Asians. For rs11190140 polymorphism (C/T) and CD risk, the risk estimate for the allele contrast was OR = 1.201 (1.136-1.269). This meta-analysis provided a robust result that persons with a G or T allele may have a moderately increased risk of CD, and suggested that rs10883365 polymorphism was also a candidate gene polymorphism for UC susceptibility.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24473197      PMCID: PMC5379238          DOI: 10.1038/srep03924

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders characterized by chronic relapsing inflammation of the gastrointestinal tract that affect 0.1% of Western populations, comprising two major forms, Crohn's disease (CD) and ulcerative colitis (UC)1. In Crohn's disease the inflammation is often transmural, whereas in ulcerative colitis the inflammation is typically confined to the mucosa. Additionally, Crohn's disease can be associated with intestinal granulomas, strictures, and fistulas, but these are not typical findings in ulcerative colitis. Although our understanding of disease pathogenesis remains incomplete, accumulating evidence suggests that that IBD is a complex, multifactorial disease partly determined by a genetic predisposition2. Strong familial aggregation, twin studies, and established genetic associations345. indicate that there is a genetic component to the disease susceptibility in IBD. Recently, sequence variations associated with IBD have been reported for several genes, including NOD2, IL23R, IRGM, ATG16L1, PTPN2, and NK2 transcription factor related and locus 3 (NKX2-3)67891011. NKX2-3, located on 10q24, is a member of a family of genes that encodes transcription factors containing homeodomains and, therefore, is implicated in basic developmental functions. During development, NKX2-3 is expressed in midgut and hindgut mesoderm and spleen, as well as in pharyngeal endoderm1213. The association between the NKX2-3 polymorphism and susceptibility of IBD was first reported in Caucasian patients14. After the first report of the association, several studies confirmed the association of tag-SNPs (rs10883365 and rs1190140) in the NKX2-3 gene with CD1516 as well as with UC in Caucasian or Asian populations171819. However, several studies could not replicate the genetic association between IBD and NKX2-3 polymorphsims152021. Thus, a quantitative synthesis may help to provide clearer evidence on the association of such genetic polymorphisms with IBD. In the present study, we conducted a meta-analysis of all eligible studies to quantitatively assess the associations between three common polymorphisms (rs10883365 and rs11190140) in the NKX2-3 gene and IBD susceptibility.

Results

Characteristics of the included studies

The combined search yielded 75 references, of which 31 were duplicate studies, 9 were reviews, 4 were about cell studies, 8 were only with abstracts, 7 reported other mutations, 1 reported other disease. Finally, a total of 15 articles were finally included. Among them, one publication15 contained data on two different subpopulations, one16 included Wellcome Trust Case Control Consortium (WTCCC) samples and replication Crohn's disease (RCD) samples, and we treated them independently. In total, 17 studies comprising 17329 cases and 18029 controls were included in the present meta-analysis111516171819202122232425262728. The 17 separate studies consisted of 13 European and 4 Asian. The distribution of genotypes in the control groups of all studies was in agreement with HWE except for 1 study19. Summaries of all included studies were summarized in Table 1, and the flow chart of study selection process was shown in Figure 1.
Table 1

Main Characteristics of Studies Involved in NKX2-3 polymorphism and Crohn's disease or ulcerative colitis Risk

  CasesControls
Author, Year of publishcationEthnicityNKX2-3 variantPhenotype StudiedNumberMales (%)Age or Age at diagnosisNumberMales (%)AgeMatching
Tanaka, 2009Asiansrs10883365CD and UCCD: 174CD: 65.5CD: 16–6139448.019–76nr
   separatelyUC: 296UC: 48.0UC: 15–79    
Meggyesi, 2010Europeansrs10883365CD and UC separatelyCD: 810CD: 53.6CD: 37.1 ± 12.6 and 26.5 ± 10.6 at diagnosis46953.540.5 ± 11.5Age and sex
Meggyesi, 2010Europeansrs10883365CD and UC separatelyUC: 428UC: 47.2UC: 43.7 ± 15.0 and 31.3 ± 13.4 at diagnosis    
Fisher, 2008Europeansrs10883365UCUC: 1841nrnr1470nrnrnr
Franke, 2008Europeansrs10883365 rs11190140CD and UC separatelyCD: 1850UC: 1103CD: 32.0CD: mean 38 and 21at diagnosis1817nrnrAge and sex
Parkes, 2007Europeansrs10883365CDCD: 1182CD: 40.3CD: mean 43.9 and 25.5 at diagnosis2024nrnrnr
Parkes, 2007Europeansrs10883365CDCD: 1748CD: 39.2CD: mean 45.7 and 26.1 at diagnosis5740nrnrnr
Yu, 2009Europeansrs10883365CDCD: 75nrnr255nrnrnr
Yamazaki, 2009Asiansrs10883365CDCD: 484CD: 72.8CD: 22.4 (7–55) at diagnosis47050.238.7(21–77) 
Pang, 2010Asiansrs10883365CDCD: 66CD: 48.5CD: 36.26 ± 11.826650.035.42 ± 13.14Age and sex
Arai, 2011Asiansrs10883365CD and UC separatelyCD: 344UC: 253nrnrnrnr243nrnrnr
Weersma, 2009Europeansrs10883365CD and UC separatelyCD: 1656UC: 1075nrnr1086nrnrnr
van der Heide, 2010Europeansrs10883365CDCD: 31034.5CD:26.6 (7.5–73.9) at diagnosis976nrnrnr
Latiano, 2011Europeansrs11190140CDCD: 1070CD: 56%nr783nrnrnr
Laukens, 2010Europeansrs11190140CDCD: 1051nrnr676nrnrnr
Peter, 2011Europeansrs11190140CDCD: 369nrnr503nrnrnr
Waterman, 2011Europeansrs11190140CDCD: 1144CD: 53%CD: 16(2–62) at diagnosis105736%nrnr

NKX2-3: NK2 transcription factor related and locus 3; CD: Crohn's disease, UC: ulcerative colitis, nr: not report.

Figure 1

Study selection procedures for a meta-analysis of NKX2-3 polymorphisms and risk of CD or UC.

NKX2-3: NK2 transcription factor related and locus 3; CD: Crohn's disease; UC: ulcerative colitis.

Quantitative synthesis

Crohn's disease

The summary of meta-analysis for the NKX2-3 polymorphisms with CD is shown in Table 2, Figure 2A and Supplementary Figure S1. Regarding rs10883365 polymorphism, the results of combined analyses comprising 8699 cases and 13540 controls revealed a significantly increased risk of CD in all genetic models. In addition, the OR was 1.481 (1.351–1.623) in carriers of two risk G alleles compared with non-risk allele carriers (GG vs AA), which was higher than the risk of one G allele carriers (GA vs AA, OR = 1.141 (1.055–1.234), suggesting a dose–response with increasing number of the variant allele. In the subgroup analysis, significantly increased risks were found both among European and Asian population. No between-study significant heterogeneity was observed in all genetic models.
Table 2

Pooled analysis for the associations between the polymorphism of NKX2-3 and the risk of Crohn's disease

VariantComparisonVariablesNo. ofSample SizeTest of associationModelTest of heterogeneity
   studiesCaseControlOR (95% CI)P-value I2(%)P-value
rs10883365G vs AOverall128699135401.226 (1.177–1.277)<0.001F0.00.968
  All in HWE9488396611.215 (1.154–1.280)<0.001F0.00.913
  European87631123671.226 (1.174–1.280)<0.001F0.00.944
  Asian4106811731.223 (1.082–1.382)0.001F0.00.613
 GG vs AAoverall106733114781.481 (1.351–1.623)<0.001F0.00.936
  All in HWE9488396611.476 (1.328–1.639)<0.001F0.00.893
  European65665103051.481 (1.342–1.635)<0.001F0.00.905
  Asian4106811731.477 (1.148–1.901)0.002F0.00.566
 GA vs AAOverall106733114781.141 (1.055–1.234)0.001F0.00.836
  All in HWE9488396611.159 (1.059–1.268)0.001F0.00.807
  European65665103051.116 (1.024–1.215)0.012F0.00.796
  Asian4106811731.280 (1.055–1.553)0.012F0.00.807
 GG + GA vs AAOverall106733114781.241 (1.153–1.336)<0.001F0.00.887
  All in HWE9488396611.254 (1.152–1.365)<0.001F0.00.846
  European65665103051.225 (1.130–1.328)<0.001F0.00.814
  Asian4106811731.328 (1.106–1.595)0.002F0.00.693
 GG vs GA + GAOverall106733114781.362 (1.263–1.468)<0.001F0.00.960
  All in HWE9488396611.345 (1.235–1.465)<0.001F0.00.948
  European65665103051.373 (1.268–1.486)<0.001F0.00.927
  Asian4106811731.297 (1.024–1.598)0.030F0.00.710
rs11190140T vs COver(Europeans)5548448361.201 (1.136–1.269)<0.001F0.00.773
  All in HWE2212114261.190 (1.080–1.311)<0.001F0.00.544
 TT vs CCOver(Europeans)3397132761.485 (1.297–1.700)<0.001F0.00.631
  All in HWE2212114261.412 (1.162–1.716)0.001F0.00.516
 TC vs CCOver(Europeans)3397132761.155 (1.029–1.298)0.015F0.00.478
  All in HWE2212114261.227 (1.033–1.458)0.020F0.00.430
 TT + TC vs CCOver(Europeans)3397132761.253 (1.122–1.398)<0.001F0.00.867
  All in HWE2212114261.289 (1.095–1.516)0.002F0.00.785
 TT vs TC + CCOver(Europeans)3397132761.344 (1.204–1.501)<0.001F50.10.135
  All in HWE2212114261.239 (1.061–1.446)0.007F45.40.176

NKX2-3: NK2 transcription factor related and locus 3; R: Random-effects model, F: fixed-effects model, HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval.

Figure 2

OR estimates with the corresponding 95% CI for the association between rs10883365 polymorphism in NKX2-3 gene and CD or UC risk.

(a): rs10883365 polymorphism and CD risk (G vs. A), (b): rs10883365 polymorphism and UC risk (G vs. A). The sizes of the squares reflect the weighting of included studies. OR: odds ratio; CI: confidence interval.

A total of 5484 patients and 4863 controls were investigated for rs11190140 variant, a significant association was found in all genetic models. (see Supplementary Fig. S1) Similar to rs10883365, the OR (OR = 1.485, P < 0.001) in carriers of 2 risk alleles was higher than that (OR = 1.155, P < 0.001) in those of 1 risk allele. No between-study heterogeneity was detected in any genetic models of rs11190140 variant and CD risk.

Ulcerative colitis

Seven studies with 4996 UC patients and 5479 controls for rs10883365 polymorphism were investigated. Meta-analysis findings of associations between rs10883365 in NKX2-3 gene and the risk of UC were shown in Table 3 and Figure 2B. Significantly increased UC risk was observed in all comparisons (G vs A: OR = 1.274 (1.175–1.382), GG vs AA: OR = 1.672 (1.474–1.896), GA vs AA = 1.207 (1.084–1.343), dominant model: OR = 1.342 (1.213–1.485), and recessive model: OR = 1.470 (1.325–1.630)). (Fig. 2B) When stratified by ethnicity, significant association was found both in European and Asian subgroups except for one genetic model in Asian (GA vs AA: OR = 1.260 (0.971–1.634)). No heterogeneity was detected in major genetic models.
Table 3

Pooled analysis for the associations between the polymorphism of NKX2-3 and the risk of ulcerative colitis

VariantComparisonVariablesNo. ofSample SizeTest of associationModelTest of heterogeneity
   studiesCaseControlOR (95% CI)P-value I2(%)P-value
rs10883365G vs AOverall7499654791.274 (1.175–1.382)<0.001R44.50.094
  All in HWE5281825761.268 (1.174–1.369)<0.001F36.50.178
  Europeans5444748421.225 (1.156–1.298)<0.001F41.10.147
  Asians25496371.452 (1.232–1.712)<0.001F0.00.176
 GG vs AAoverall6392143931.672 (1.474–1.896)<0.001F20.10.282
  All in HWE5281825761.619 (1.387–1.889)<0.001F30.50.218
  Europeans4337237561.609 (1.404–1.844)<0.001F26.00.255
  Asians25496372.078 (1.500–2.878)<0.001F0.00.654
 GA vs AAOverall6392143931.207 (1.084–1.343)0.001F0.00.901
  All in HWE5281825761.242 (1.090–1.416)0.001F0.00.905
  Europeans4337237561.196 (1.063–1.345)0.003F0.00.814
  Asians25496371.260 (0.971–1.634)0.082F0.00.466
 GG + GA vs AAOverall6392143931.342 (1.213–1.485)<0.001F0.00.801
  All in HWE5281825761.356 (1.199–1.533)<0.001F0.00.688
  Europeans4337237561.317 (1.179–1.472)<0.001F0.00.767
  Asians25496371.467 (1.151–1.869)0.002F0.00.454
 GG vs GA + GAOverall6392143931.470 (1.325–1.630)<0.001F43.90.112
  All in HWE5281825761.391 (1.223–1.581)<0.001F41.20.146
  Europeans4337237561.455 (1.202–1.761)<0.001R53.90.089
  Asians25496371.534 (1.160–2.028)<0.001F0.00.894

NKX2-3: NK2 transcription factor related and locus 3; R: Random-effects model, F: fixed-effects model, HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval.

Sensitivity analyses and cumulative meta-analysis

Sensitivity analysis showed no single study qualitatively changed the pooled ORs. (see Supplementary Fig. S2 and S3) Moreover, there was a study which deviated from HWE, when excluded, the estimated pooled OR still did not change at all, indicating that the results of this meta-analysis were high stable. (Table 2 and 3) In the cumulative meta-analysis, the pooled ORs tended to be stable and the associations tended toward significant associations with accumulation of more data over time between rs10883365 or rs11190140 variant and CD risk, as well as between rs10883365 and UC risk (see Fig. 3 and Supplementary Fig. S4).
Figure 3

Cumulative meta-analysis on the association between rs10883365 polymorphism and CD or UC risk.

(a): rs10883365 variant and CD risk (G vs. A); (b): rs10883365 variant and UC risk (G vs. A). Pooled OR estimates with the 95% CI as information accumulates at the end of each year (left column). CD: Crohn's disease; UC: ulcerative colitis; OR: odds ratio; CI: confidence interval.

Publication bias

Funnel plots and Egger's test were performed to assess publication bias. No publication bias was detected for rs10883365 polymorphism. (G vs A: t = −0.04, p = 0.966 and t = 1.56, p = 0.181 in CD and UC, respectively). Similarly, no publication bias was detected for T vs C contrast of rs11190140 polymorphism in CD. (see Supplementary Fig. S6) As shown in Supplementary Figure S5, the shapes of the funnel plots did not indicate any evidence of obvious asymmetry for rs10883365 variant and CD or UC risk.

Discussion

Presently the mechanisms of the etiology and progression of IBD are far from clear. Several genes have been identified to be associated with IBD risk, including NOD2, NKX2-3 and IL-23. Recently, genome-wide association studies (GWAS) have identified SNPs implicating hundreds of replicated loci for common traits and becomes a powerful tool to detect the susceptibility genes in the IBD diseases162930. Several GWAS and GWAS meta-analysis have provided strong evidences for the association between NKX2-3 single nucleotide polymorphisms (SNPs) (rs6584283 and rs4409764) and risk of IBDs313233. However, two common variants (rs10883365 and rs11190140) in NKX2-3 gene were not included in the GWAS meta-analyses. A meta-analysis can combine results from individual studies to overcome the limitation of small sample sizes and inadequate statistical power, and produce a single estimate of the major effect. Recently, accumulated meta-analysis has been performed to investigate the association of genetic variants with susceptibility to CD or UC. Polymorphisms in several genes, including ATG16L1 T300A34, TGF-α G308A35, MIF G173C36, OCTN1 C1672T37, CD14 C260T38 and MDR1 C3435T39, were identified as risk factors of CD or UC. Patients with mutant allele of NOD1 rs695857140 and Pro12Ala41 might have a decreased susceptibility to IBD. Additionally, some genetic variants were not association with CD or UC risk, such as MDR1 C1236T39, IL-10 G1082A42, and IL-18 A607C43. Therefore, we saw the need to perform pooled analyses with larger sample size by summarizing previous case–control or cohort studies in order to better understand the association between the NKX2-3 variants and IBD risk. NKX2-3, located on chromosome 10q24, is predominantly expressed in mesoderm of midgut and hindgut during embryonic mouse development12. Postnatally, Nkx2-3 expression continues in gut mesenchyme and in spleen. In addition, mice lacking Nkx2-3 exhibit severe defects in gut development; primarily in the epithelium of the small intestine44. The perturbations of the gut tissue architecture lead to early postnatal death presumably due to digestive malfunctions. Moreover, analysis of Nkx2-3-deficient mice has revealed a critical role for NKX2-3 in spleen development and in establishing the correct environment for normal B cell development and T cell dependent immune response4546. Recently, associations between the two common polymorphisms (rs10883365 and rs11190140) in NKX2-3 gene and susceptibility of CD or UC have been reported in several studies. To the best of our knowledge, the present study involving 37039 subjects represents the first comprehensive meta-analysis investigating the association between NKX2-3 polymorphisms (rs10883365 and rs11190140) and IBD susceptibility. For the analysis of rs10883365 polymorphism, a significantly increased CD risk was observed in all genetic models. In the ethnicity-stratified analyses, significant association was found both in Asian and European populations. Similar results were found between the rs11190140 variant and risk of CD where a significant association was found European population (no Asian population reported). No between-study heterogeneity was observed in most genetic models. Sensitivity analysis indicated that when excluding studies departed from HWE, the pooled OR still did not change, demonstrating the results of this meta-analysis were stable. Since these two SNPs are close to each other, we use 1000 Genomes Pilot sequence data to identify whether these SNPs are in linkage disequilibrium (LD) (r2 > 0.8). The results indicated that rs10883365 and rs11190140 are in perfect LD (r2 = 1.0). CD and UC, as two major subtypes of IBD, are believed to share overlapping but distinct clinical and pathological features, and have great differences in genetic backgrounds11. Some genes, such as NOD2 and ATG16L1, were associated with CD, but not with UC4748. However, recent GWAS meta-analysis identified 163 IBD loci that meet genome-wide significance thresholds, 50 of these have an indistinguishable effect size in UC and CD, including IL23R (rs11209026), IL10 (rs3024505) and MST1 (rs3197999). In the present meta-analysis, significant association between rs10883365 and risk of UC was found in all genetic models. When stratified by ethnicity, similar correlation was observed both in Asians and Europeans. No between-study heterogeneity existed in major genetic models. Sensitivity analysis showed no single study qualitatively changed the pooled ORs. Moreover, excluding studies departed from HWE, the pooled OR still did not change, demonstrating the results of this meta-analysis were stable. These results indicated that rs10883365 polymorphism in NKX2-3 gene may be significantly associated with both CD and UC. By combining the data of individual studies, we increased the statistical power to detect subtle associations, however,several limitations should be considered in our meta-analysis. Only studies published in the English and Chinese language were included in this meta-analysis; therefore, publication bias may have occurred. In addition, this meta-analysis was designed to analyze single polymorphism, a haplotype analysis may have been more powerful for finding significant associations with UC and CD. Finally, gene–environment interactions were not analyzed because of insufficient data. Despite these limitations, our results still yield statistical results. Taken together, we expand previously individual studies on IBD by suggesting that NKX2-3 gene rs10883365 polymorphisms might contribute to the occurrence of both CD and UC, and suggested that persons with a T allele of rs1190140 variant might have a significantly increased risk of CD. Further studies or large case-control studies, especially studies emphasizing genotype–phenotype interaction should be performed to clarify possible roles of NKX2-3in IBD. Moreover, studies involved in NKX2-3 polymorphisms in different populations with larger sample size might need to be performed.

Methods

Search strategy

We searched PubMed and Embase to identify genetic association studies of the rs10883365 or rs11190140 polymorphism and IBD risks. Electronic searches were performed by using the following search terms: ‘Inflammatory Bowel Disease' or ‘IBD', ‘Crohn's disease' or ‘CD', ‘ulcerative colitis' or ‘UC', ‘NKX2-3', ‘rs10883365', or ‘rs11190140', (the last search update was 1 September 2013). In addition, the reference lists of reviews and retrieved articles were checked by hand-search for additional potential studies. A study reported results from more than one population was considered as separate studies.

Inclusion and exclusion criteria

Studies were considered eligible if they had to meet the following criteria: (1) association between NKX2-3 polymorphisms and risk of IBD (CD or UC), (2) case-control or cohort studies. Studies were excluded for the following reasons: (1) articles only with an abstract and review articles (2) no control population, (3) studies considered overlapped with other studies.

Data extraction

Two authors extracted the following data independently from each of the eligible articles: first author, publication year, ethnicity of the participants involved (categorized as Europeans or Asians), number of cases and controls, information (age, mean age at diagnosis and sex) of cases and controls, and number of genotypes or allele frequency in cases and controls. Study authors were contacted for detailed data when there was insufficient information to determine the relationship between genetic polymorphism and IBD risk. Disagreements were resolved by discussion between the two authors.

Statistical analysis

Pooled odds ratios (ORs) and 95% confidence intervals (CIs) used to assess the strength of the association between IBD risk (CD or UC) and NKX2-3 polymorphisms (rs10883365 or rs11190140). The significance of the pooled OR was determined by the Z-test; a P-value of <0.05 was considered significant. The Hardy-Weinberg equilibrium (HWE) in the control group was assessed, and a P < 0.05 was considered as significant disequilibrium. For rs10883365 polymorphism, the pooled ORs were estimated for G versus A, GG versus AA, GA versus AA, dominant model (GG + GA versus AA), and recessive model (GG versus GA + AA). Because of only three studies194950 available for the association between rs11190140 variant and UC risk, we have performed meta-analysis of correlation between rs11190140 polymorphism and CD risk. Subgroup analysis was performed according to ethnicity. Between-study heterogeneity was evaluated by using the Chi-square based Q test and I2 test51. Heterogeneity was considered significant for P < 0.10, and a random-effects model was used, otherwise, fixed-effects model was used. In addition, if heterogeneity was detected, Galbraith plots were used to visualize the impact of individual studies on the overall homogeneity, which spot the outliers as the possible major sources of heterogeneity5253. Moreover, a meta-regression was used to delineate the major sources of between-study heterogeneity54. Sensitivity analysis was carried out to evaluate the stability of the results after sequential removal of each study or by excluding those studies deviated from HWE. In addition, cumulative meta-analyses were carried out for each polymorphism through assortment of studies with publication time. Graphical evaluation of funnel plots and Egger's linear regression test were performed to assess publication bias55. If significant publication bias was detected, ORs and 95% CI would be adjusted by trim and fill methods56. All statistical analyses were performed by STATA software, version 12 (StataCorp LP, College Station, Texas).
  54 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis.

Authors:  Matti Waterman; Wei Xu; Joanne M Stempak; Raquel Milgrom; Charles N Bernstein; Anne M Griffiths; Gordon R Greenberg; A Hillary Steinhart; Mark S Silverberg
Journal:  Inflamm Bowel Dis       Date:  2010-12-10       Impact factor: 5.325

Review 3.  Classification of inflammatory bowel disease: the old and the new.

Authors:  Severine Vermeire; Gert Van Assche; Paul Rutgeerts
Journal:  Curr Opin Gastroenterol       Date:  2012-07       Impact factor: 3.287

4.  NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease.

Authors:  T Molnar; P Hofner; F Nagy; P L Lakatos; S Fischer; L Lakatos; A Kovacs; I Altorjay; M Papp; K Palatka; P Demeter; Z Tulassay; T Nyari; P Miheller; J Papp; Y Mandi; J Lonovics
Journal:  Dig Liver Dis       Date:  2007-10-26       Impact factor: 4.088

Review 5.  Is there evidence to claim or deny association between variants of the multidrug resistance gene (MDR1 or ABCB1) and inflammatory bowel disease?

Authors:  Elias Zintzaras
Journal:  Inflamm Bowel Dis       Date:  2011-09-01       Impact factor: 5.325

6.  Evidence for significant overlap between common risk variants for Crohn's disease and ankylosing spondylitis.

Authors:  Debby Laukens; Michel Georges; Cécile Libioulle; Cynthia Sandor; Myriam Mni; Bert Vander Cruyssen; Harald Peeters; Dirk Elewaut; Martine De Vos
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

7.  Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: a Study in the Spanish population and a meta-analysis.

Authors:  Ana Márquez; Concepción Núñez; Alfonso Martínez; Juan Luis Mendoza; Carlos Taxonera; Miguel Fernández-Arquero; Manuel Díaz-Rubio; Emilio G de la Concha; Elena Urcelay
Journal:  Inflamm Bowel Dis       Date:  2009-11       Impact factor: 5.325

8.  Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.

Authors:  Carl A Anderson; Gabrielle Boucher; Charlie W Lees; Andre Franke; Mauro D'Amato; Kent D Taylor; James C Lee; Philippe Goyette; Marcin Imielinski; Anna Latiano; Caroline Lagacé; Regan Scott; Leila Amininejad; Suzannah Bumpstead; Leonard Baidoo; Robert N Baldassano; Murray Barclay; Theodore M Bayless; Stephan Brand; Carsten Büning; Jean-Frédéric Colombel; Lee A Denson; Martine De Vos; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Rudolf S N Fehrmann; James A B Floyd; Timothy Florin; Denis Franchimont; Lude Franke; Michel Georges; Jürgen Glas; Nicole L Glazer; Stephen L Guthery; Talin Haritunians; Nicholas K Hayward; Jean-Pierre Hugot; Gilles Jobin; Debby Laukens; Ian Lawrance; Marc Lémann; Arie Levine; Cecile Libioulle; Edouard Louis; Dermot P McGovern; Monica Milla; Grant W Montgomery; Katherine I Morley; Craig Mowat; Aylwin Ng; William Newman; Roel A Ophoff; Laura Papi; Orazio Palmieri; Laurent Peyrin-Biroulet; Julián Panés; Anne Phillips; Natalie J Prescott; Deborah D Proctor; Rebecca Roberts; Richard Russell; Paul Rutgeerts; Jeremy Sanderson; Miquel Sans; Philip Schumm; Frank Seibold; Yashoda Sharma; Lisa A Simms; Mark Seielstad; A Hillary Steinhart; Stephan R Targan; Leonard H van den Berg; Morten Vatn; Hein Verspaget; Thomas Walters; Cisca Wijmenga; David C Wilson; Harm-Jan Westra; Ramnik J Xavier; Zhen Z Zhao; Cyriel Y Ponsioen; Vibeke Andersen; Leif Torkvist; Maria Gazouli; Nicholas P Anagnou; Tom H Karlsen; Limas Kupcinskas; Jurgita Sventoraityte; John C Mansfield; Subra Kugathasan; Mark S Silverberg; Jonas Halfvarson; Jerome I Rotter; Christopher G Mathew; Anne M Griffiths; Richard Gearry; Tariq Ahmad; Steven R Brant; Mathias Chamaillard; Jack Satsangi; Judy H Cho; Stefan Schreiber; Mark J Daly; Jeffrey C Barrett; Miles Parkes; Vito Annese; Hakon Hakonarson; Graham Radford-Smith; Richard H Duerr; Séverine Vermeire; Rinse K Weersma; John D Rioux
Journal:  Nat Genet       Date:  2011-02-06       Impact factor: 38.330

9.  Common variants at five new loci associated with early-onset inflammatory bowel disease.

Authors:  Marcin Imielinski; Robert N Baldassano; Anne Griffiths; Richard K Russell; Vito Annese; Marla Dubinsky; Subra Kugathasan; Jonathan P Bradfield; Thomas D Walters; Patrick Sleiman; Cecilia E Kim; Aleixo Muise; Kai Wang; Joseph T Glessner; Shehzad Saeed; Haitao Zhang; Edward C Frackelton; Cuiping Hou; James H Flory; George Otieno; Rosetta M Chiavacci; Robert Grundmeier; Massimo Castro; Anna Latiano; Bruno Dallapiccola; Joanne Stempak; Debra J Abrams; Kent Taylor; Dermot McGovern; Gary Silber; Iwona Wrobel; Antonio Quiros; Jeffrey C Barrett; Sarah Hansoul; Dan L Nicolae; Judy H Cho; Richard H Duerr; John D Rioux; Steven R Brant; Mark S Silverberg; Kent D Taylor; M Michael Barmuda; Alain Bitton; Themistocles Dassopoulos; Lisa Wu Datta; Todd Green; Anne M Griffiths; Emily O Kistner; Michael T Murtha; Miguel D Regueiro; Jerome I Rotter; L Philip Schumm; A Hillary Steinhart; Stephen R Targan; Ramnik J Xavier; Cécile Libioulle; Cynthia Sandor; Mark Lathrop; Jacques Belaiche; Olivier Dewit; Ivo Gut; Simon Heath; Debby Laukens; Myriam Mni; Paul Rutgeerts; André Van Gossum; Diana Zelenika; Denis Franchimont; J P Hugot; Martine de Vos; Severine Vermeire; Edouard Louis; Lon R Cardon; Carl A Anderson; Hazel Drummond; Elaine Nimmo; Tariq Ahmad; Natalie J Prescott; Clive M Onnie; Sheila A Fisher; Jonathan Marchini; Jilur Ghori; Suzannah Bumpstead; Rhian Gwillam; Mark Tremelling; Panos Delukas; John Mansfield; Derek Jewell; Jack Satsangi; Christopher G Mathew; Miles Parkes; Michel Georges; Mark J Daly; Melvin B Heyman; George D Ferry; Barbara Kirschner; Jessica Lee; Jonah Essers; Richard Grand; Michael Stephens; Arie Levine; David Piccoli; John Van Limbergen; Salvatore Cucchiara; Dimitri S Monos; Stephen L Guthery; Lee Denson; David C Wilson; Straun F A Grant; Mark Daly; Mark S Silverberg; Jack Satsangi; Hakon Hakonarson
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

10.  Association between CD14 gene C-260T polymorphism and inflammatory bowel disease: a meta-analysis.

Authors:  Zhengting Wang; Jiajia Hu; Rong Fan; Jie Zhou; Jie Zhong
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more
  4 in total

1.  Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.

Authors:  Julie J Paik; Livia Casciola-Rosen; Joseph Yusup Shin; Jemima Albayda; Eleni Tiniakou; Doris G Leung; Laura Gutierrez-Alamillo; Jamie Perin; Liliana Florea; Corina Antonescu; Sherry G Leung; Grazyna Purwin; Andrew Koenig; Lisa Christopher-Stine
Journal:  Arthritis Rheumatol       Date:  2021-03-24       Impact factor: 10.995

2.  Population-scale tissue transcriptomics maps long non-coding RNAs to complex disease.

Authors:  Olivia M de Goede; Daniel C Nachun; Nicole M Ferraro; Michael J Gloudemans; Abhiram S Rao; Craig Smail; Tiffany Y Eulalio; François Aguet; Bernard Ng; Jishu Xu; Alvaro N Barbeira; Stephane E Castel; Sarah Kim-Hellmuth; YoSon Park; Alexandra J Scott; Benjamin J Strober; Christopher D Brown; Xiaoquan Wen; Ira M Hall; Alexis Battle; Tuuli Lappalainen; Hae Kyung Im; Kristin G Ardlie; Sara Mostafavi; Thomas Quertermous; Karla Kirkegaard; Stephen B Montgomery
Journal:  Cell       Date:  2021-04-16       Impact factor: 66.850

3.  Association between the CD24 Ala57Val polymorphism and risk for multiple sclerosis and systemic lupus erythematosus: a meta-analysis.

Authors:  Jian Huang; Yaqi Yang; Zibin Liang; Miaomiao Kang; Ying Kuang; Feng Li
Journal:  Sci Rep       Date:  2015-04-01       Impact factor: 4.379

Review 4.  Nkx2-3-A Slippery Slope From Development Through Inflammation Toward Hematopoietic Malignancies.

Authors:  Dóra Vojkovics; Zoltán Kellermayer; Béla Kajtár; Giovanna Roncador; Áron Vincze; Péter Balogh
Journal:  Biomark Insights       Date:  2018-02-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.